A Review on Iron Chelators in Treatment of Iron Overload Syndromes

Area of Science:

• Hematology
• Pharmacology
• Internal Medicine

Background:

• Iron overload, often resulting from regular blood transfusions, can lead to severe organ damage, particularly in the liver and heart.
• Effective management of iron overload is crucial for patients with chronic transfusion-dependent anemias.
• Current therapeutic strategies primarily involve iron chelation therapy to prevent toxic iron accumulation.

Approach:

• This review systematically evaluates the efficacy and safety of major iron chelators based on recent clinical studies.
• It compares Deferoxamine, Deferiprone, and Deferasirox, the primary US FDA-approved agents.
• The analysis considers their distinct advantages, disadvantages, target patient populations, and clinical applications.

Key Points:

• Deferoxamine, Deferiprone, and Deferasirox exhibit varied pharmacokinetic profiles and routes of administration.
• Each chelator has specific indications, contraindications, and side effect profiles that influence treatment decisions.
• Patient-specific factors, including disease severity and comorbidities, play a significant role in selecting the optimal iron chelator.

Conclusions:

• Choosing the most effective iron chelator requires careful consideration of individual patient characteristics and the specific clinical context.
• Further research is needed to establish clearer guidelines for iron chelator selection in complex cases.
• Optimizing iron chelation therapy is essential for improving long-term outcomes and quality of life in patients with iron overload disorders.